Brief: Cidara Therapeutics Announces Janssen’S Election To Proceed Under Its License Agreement Relating To Novel Drug-FC Conjugates Targeting Influenza

Cidara Therapeutics

06/09/2023 16:18

Cidara Therapeutics Inc  CDTX.O :
    * CIDARA THERAPEUTICS ANNOUNCES JANSSEN’S ELECTION TO
PROCEED
UNDER ITS LICENSE AGREEMENT RELATING TO NOVEL DRUG-FC CONJUGATES
TARGETING INFLUENZA
    * CIDARA THERAPEUTICS INC - CIDARA TO RECEIVE A $7 MILLION
MILESTONE PAYMENT AND IS ELIGIBLE TO RECEIVE AN ADDITIONAL $685
MILLION IN MILESTONES, PLUS ROYALTIES
    * CIDARA THERAPEUTICS INC - RESPONSIBILITY FOR FUTURE
DEVELOPMENT,
MANUFACTURING AND COMMERCIALIZATION ACTIVITIES OF CD388 WILL BE
ASSUMED BY JANSSEN
    * CIDARA THERAPEUTICS INC -  JANSSEN INTENDS TO TRANSFER ITS
RIGHTS AND OBLIGATIONS UNDER AGREEMENT TO ANOTHER ENTITY

Source text for Eikon:  ID:nGNX7lwmkv 
Further company coverage:  CDTX.O